Fast Locator 2011-2012: Lonza - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Lonza



A HISTORY OF INNOVATION
In 1897, Lonza was founded on the banks of the river Lonza in the Swiss Alps by adventurous entrepreneurs. Today, Lonza continues to embody that pioneering spirit as a leading innovator and partner for the pharmaceutical, healthcare, nutrition, personal care, cosmetic, industrial biotech and life science industries.

PROVEN TRACK RECORD
For over 25 years, Lonza Custom Manufacturing has been helping emerging and large biotechnology and pharmaceutical companies improve and advance their products. Whether for clinical or commercial supply, Lonza’s complete set of development services, industry-leading manufacturing processes, and broad chemical and biotechnology platforms enable your products to reach their full potential.

EXTENSIVE CAPABILITIES & EXPERIENCE
Active pharmaceutical ingredients (APIs), highly potent APIs, advanced intermediates, fine chemicals, nutraceuticals, cosmeceuticals, antibody drug conjugates, peptides, vaccines, plasmid DNA, recombinant novel proteins, monoclonal antibodies, antibody fragments, cell-based therapeutics, research products and media services … Lonza has the know-how and experience to handle almost any pharmaceutical or biotechnology challenge, around the globe.


COMPLETE PROCESS R&D SERVICES:

  • AggreSolve Protein Aggregation Predictor
  • The GS Gene Expression System
  • XS Microbial Expression Technologies
  • Cell line construction
  • Strain design
  • Bio/catalyst design
  • Process development
  • Process scale-up
  • Process validation
  • Process transfer
  • Technology development
  • Regulatory support

WORLDWIDE, STATE-OF-THE-ART FACILITIES
North America: Portsmouth, NH; Hopkinton, MA; Walkersville, MD
Europe: Slough, UK; Kourim, CZ; Porrino, ES; Braine, BE; Verviers, BE
Asia: Nansha, CN; Singapore, SG


Contact:

Lonza
Muenchensteinerstr. 38
CH-4002 Basel
Switzerland
+41 61 316 8111
contact@lonza.com

Website:

www.lonza.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here